Publication details

Léčba idelalisibem u pacienta s nežádoucím účinky ibrutinibu

Title in English Treatment of patient with Idealisib due to side effects of Ibrutinib
Authors

NĚMCOVÁ Lucie BRYCHTOVÁ Yvona DOUBEK Michael

Year of publication 2016
Type Popularization text
MU Faculty or unit

Faculty of Medicine

Citation
Attached files
Description The prognosis of relapsed form of chronic lymfocytic leukemia is poor. This case study describes a patient with CLL, who is treated with several lines of therapy. In the 5th line of the treatment one of the new inhibitor of BCR signaling pathway is administered - Ibrutinib. Although it leads to induce partial remission, a hemorrhage very frequent side effect appears. Therefore other BCR signaling inhibitor is used - inhibitor PI3K Idealisib - which finally provides better long-term therapeutic effects.

You are running an old browser version. We recommend updating your browser to its latest version.

More info